Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

Renal Function Assessment: Core Responsibilities of Clinical Pathologists and Laboratory Technicians in Diagnostic Evaluation

Mohammad Raja Aljehani[1], Abdulrahman Ali Alhayek [2] , Awad bin Dakhil bin Abdullah Al Shammari[3]

[1] Prince Mohammed Ibn Abdulaziz Hospital For National Guard, LABORATORY TECHNICIAN
[2] Ministry Of Health ,Al-Mithnab General Hospital – Qassim Health Cluster
[3] Ministry Of Health , Northern Borders, Shu'bah General Hospital

Abstract

Background: The kidneys play a vital role in maintaining homeostasis by filtering metabolic waste, regulating electrolytes, and producing hormones. Chronic kidney disease (CKD) affects approximately 14% of the population, with hypertension and diabetes being leading causes. Accurate renal function assessment is crucial for early detection, disease monitoring, and treatment planning.

Aim: This article reviews the core responsibilities of clinical pathologists and laboratory technicians in evaluating renal function, focusing on diagnostic tests, methodologies, and emerging biomarkers.

Methodology: The study examines various renal function tests, including glomerular filtration rate (GFR) estimation (using creatinine, cystatin C, and equations like CKD-EPI), blood urea nitrogen (BUN), albuminuria, and tubular function tests. It also discusses specimen collection, interfering factors, and novel biomarkers.

Results: Serum creatinine remains the most common marker for GFR estimation, though it has limitations, including delayed detection of early kidney injury. Cystatin C offers improved accuracy, particularly in patients with abnormal muscle mass. Albuminuria is a key indicator of glomerular damage, while tubular function tests help diagnose specific renal disorders. Novel biomarkers like neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) show promise in early AKI detection.

Conclusion: Renal function tests are essential for diagnosing and managing kidney disease. While traditional markers like creatinine and BUN remain widely used, newer biomarkers and advanced equations enhance diagnostic precision. Clinical pathologists and laboratory technicians play a critical role in ensuring accurate testing and interpretation.

Keywords: Renal function, GFR, creatinine, cystatin C, albuminuria, CKD, AKI, biomarkers.

Introduction

The kidneys serve as essential organs responsible for eliminating metabolic waste and harmful substances, including urea, creatinine, and uric acid. They maintain homeostasis by regulating the volume of extracellular fluids, the osmotic concentration of the serum, and the balance of electrolytes. Additionally, they contribute to endocrine function through the secretion of erythropoietin, the synthesis of 1,25-dihydroxy vitamin D, and the production of renin. The nephron, the kidney's fundamental structural and functional unit, comprises the glomerulus, proximal tubule, distal tubule, and collecting duct, all of which collaborate in filtration and reabsorption processes. The evaluation of renal function plays a critical role in the clinical management of patients with kidney-related disorders or systemic diseases with renal involvement. Renal function tests serve multiple purposes: they assist in detecting kidney disease, tracking the kidneys' response to therapeutic interventions, and evaluating disease progression. These tests provide quantitative biochemical markers that reflect the kidneys' filtration and excretory capacity, supporting diagnosis and treatment planning. Epidemiological data from the National Institutes of Health estimate that chronic kidney disease (CKD) affects approximately 14% of the population. This significant prevalence highlights the importance of early detection and monitoring strategies in at-risk groups. On a global scale, hypertension and diabetes remain the leading etiologies

*Corresponding author e-mail: Mrj-medo@hotmail.com (Mohammad Raja Aljehani).
Received date: 3 Nov 2024 Revised date: 25 Nov 2024. Accepted date: 25 Dec 2024

contributing to the development and progression of CKD [1][2][3][4]. Effective biochemical assessment is therefore essential in both primary and specialized care settings. This overview presents current approaches to renal function assessment, emphasizing the clinical relevance of biochemical tests in detecting and managing kidney disease.

Specimen Collection:

The process of specimen collection is determined by the nature of the renal function test being conducted. For standard assessments such as serum creatinine and blood urea nitrogen (BUN), no specific patient preparation is usually required. These tests typically rely on a random blood sample, which is sufficient under normal circumstances. However, recent intake of a protein-rich meal can lead to transient elevations in serum creatinine and urea levels, potentially affecting the interpretation of results. Moreover, the patient's hydration status significantly influences BUN concentrations. Dehydration, in particular, can result in falsely elevated BUN values due to hemoconcentration, which may not accurately reflect renal impairment. In procedures requiring timed urine collections, such as the 24-hour urine creatinine clearance test, the accuracy of the collected data heavily depends on the patient's compliance with proper collection techniques over the entire period. Incomplete or excessive collection volumes can distort clearance values, leading to erroneous conclusions about kidney function. As a result, shorter collection durations, such as a 5- to 8-hour sample, may offer a more reliable alternative, especially when performed outside hospital environments where patient supervision is limited [5][6][7]. For urine analysis, midstream urine samples are recommended due to their reduced risk of contamination. This method minimizes the presence of epithelial cells and commensal microorganisms, both of which can interfere with microscopic and biochemical analysis. Ensuring the quality of the sample at the point of collection is essential for obtaining valid and clinically meaningful results, especially in the context of diagnosing renal pathology or urinary tract infections [5][6][7].

Procedures

Several clinical laboratory investigations are employed to evaluate kidney function in medical settings. Among the most relevant and widely used are tests that estimate the glomerular filtration rate (eGFR) and measure proteinuria, particularly albuminuria. These tests provide practical, quantitative insights into renal performance and are used routinely in both diagnostic and monitoring contexts [7].

Glomerular Filtration Rate

Glomerular filtration rate (GFR) is considered the most accurate overall marker of kidney function. It reflects the volume of plasma filtered through the glomeruli each minute and serves as a reliable measure of the kidneys' ability to clear substances from the bloodstream. In healthy adult males, GFR typically ranges from 90 to 120 mL/min, but this value declines with age. Research indicates a reduction of approximately 7.5 mL/min/1.73 m² per decade after age 30. Consequently, a healthy 70-year-old may present a GFR close to 60 mL/min/1.73 m² [8][9][8]. An ideal marker for GFR should be produced at a constant rate within the body, filtered freely at the glomerulus, not reabsorbed or secreted in the tubules, and eliminated only through the kidneys. Since no endogenous substance meets all these criteria, clinicians often rely on exogenous compounds. Inulin clearance is the reference method for GFR measurement, involving infusion and subsequent blood and urine sampling. Other alternatives include the use of radioisotopes like chromium-51 EDTA and technetium-99 DTPA. Iohexol, a non-radioactive contrast agent, has emerged as a preferred option in pediatric populations due to its safety and efficacy. Despite their accuracy, exogenous marker-based methods are time-consuming, costly, and require specialized laboratory facilities. These limitations have shifted focus toward endogenous markers, which are more accessible for routine use [8][9][8].

Creatinine

Creatinine remains the most frequently used endogenous marker to assess glomerular filtration. Its clearance, calculated from urine and blood samples, offers a practical estimation of GFR. Typically, a 24-hour urine collection is employed, although shorter periods of 5 to 8 hours may provide more accurate results due to better patient compliance. The creatinine clearance formula is $C = (UCr \times V) / PCr$, where C is clearance, U is urinary creatinine concentration, V is urine flow rate, and P is plasma creatinine concentration. Adjustments based on body surface area are necessary to ensure accurate interpretation. However, creatinine has known limitations. It is partially secreted by the renal tubules, which leads to an overestimation of true GFR by 10% to 20%. Moreover, the amount of creatinine generated daily is influenced by muscle mass. Therefore, differences in age, sex, diet, and physiological states such as pregnancy can affect serum creatinine levels. Red meat consumption, for instance, can cause a temporary rise in serum creatinine by up to 30%. Also, serum creatinine often does not increase until there is a substantial loss of kidney function—up to 50%—which reduces its sensitivity in early disease detection [8][9][8].

To overcome these limitations, eGFR is estimated using standardized equations that incorporate serum creatinine levels. The two primary equations are the Modified Diet in Renal Disease (MDRD) and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. The CKD-EPI formula provides more accurate estimates across a wider range of kidney function and is better suited to diverse populations [10][11][12]. Recent advancements include equations combining creatinine and cystatin C, a protein less influenced by muscle mass. Studies such as those by Inker et al. have shown these equations, which exclude race, improve the accuracy of GFR estimates [13]. There is ongoing debate regarding the use of race in GFR calculations. Historically, Black race was included as a correction factor based on assumptions about higher average muscle mass. However, recent evidence suggests this may

not apply universally, and race-based adjustments can lead to inaccuracies across different populations [14][15][16][17]. Many experts now recommend using cystatin C in place of creatinine for estimating GFR, particularly in patients with unusual muscle mass or in multi-ethnic populations. However, due to limited routine availability, creatinine-based CKD-EPI equations remain the standard in most clinical laboratories. The National Kidney Foundation and the American Society of Nephrology support the use of the CKD-EPI creatinine-only equation as the default for clinical reporting [15].

The CKD-EPI equation used is:

eGFR = 142 × min(SCr/κ,1)^α × max(SCr/κ,1)^−1.200 × 0.9938^Age × 1.012 (if female),

where SCr is serum creatinine, κ is 0.7 for females and 0.9 for males, and α is −0.329 for females and −0.411 for males. In children, different equations are required. The Schwartz bedside equation and its updated versions, such as the Schwartz-Lyon formula, provide more accurate GFR estimates for pediatric patients. These use serum creatinine and height to derive values. In adolescents and young adults, modified versions of CKD-EPI incorporating age-specific creatinine growth curves, known as CKD-EPI40, have demonstrated improved accuracy [21][22][23].

Staging of Chronic Kidney Disease

The Kidney Disease Improving Global Outcomes (KDIGO) classification system outlines stages of chronic kidney disease based on GFR values:

- Stage 1: GFR > 90 mL/min/1.73 m²
- Stage 2: GFR 60–89 mL/min/1.73 m²
- Stage 3a: GFR 45–59 mL/min/1.73 m²
- Stage 3b: GFR 30–44 mL/min/1.73 m²
- Stage 4: GFR 15–29 mL/min/1.73 m²
- Stage 5: GFR < 15 mL/min/1.73 m² (end-stage renal disease)

These stages assist clinicians in categorizing disease severity and guiding treatment decisions. However, since they rely on serum creatinine, they inherit its limitations and require correction for variables such as age, sex, and muscle mass. Furthermore, these equations assume stable creatinine levels, limiting their accuracy in situations involving rapid changes in renal function. Continued development of biomarkers and more refined equations remains a priority in nephrology research [21][22][23].

Blood Urea Nitrogen

Urea, commonly referred to in clinical settings as blood urea nitrogen (BUN), is a nitrogen-based compound generated in the liver during the breakdown of proteins through the urea cycle. Approximately 85% of circulating urea is excreted via the kidneys, while the remainder is eliminated through the gastrointestinal tract. Serum urea concentrations rise when renal clearance is impaired, which is seen in both acute and chronic renal failure. However, elevated BUN levels can also result from non-renal causes such as upper gastrointestinal bleeding, dehydration, catabolic states, and the consumption of high-protein diets. Conversely, reduced urea levels are observed in states of protein malnutrition, prolonged fasting, low-protein intake, or severe hepatic dysfunction. Although creatinine provides a more precise evaluation of renal function, BUN often increases earlier in the course of renal disease, which gives it clinical utility in early detection. When BUN levels are elevated, the BUN-to-creatinine ratio becomes a useful tool to differentiate between pre-renal and intrinsic renal pathologies. In pre-renal conditions such as dehydration or heart failure, this ratio typically approaches 20:1, whereas intrinsic renal diseases usually produce a ratio closer to 10:1. Extremely elevated ratios, sometimes exceeding 30:1, are suggestive of gastrointestinal bleeding, where reabsorbed blood proteins contribute to increased urea production [24].

Cystatin C

Cystatin C is a low-molecular-weight protein produced continuously by all nucleated cells in the body. It acts as a protease inhibitor and is secreted into the bloodstream at a constant rate. Like creatinine, it is freely filtered by the glomeruli, but its renal processing is distinct. Once filtered, cystatin C is almost entirely reabsorbed and metabolized by the proximal tubular cells, meaning it does not appear in urine in significant quantities under normal conditions. Therefore, serum concentrations of cystatin C provide a direct reflection of glomerular filtration efficiency. One major clinical advantage of cystatin C over creatinine is that its levels are not influenced by variables such as muscle mass, age, or dietary protein intake. This makes it especially useful in populations where creatinine-based GFR estimation may be inaccurate, such as the elderly, children, malnourished individuals, or those with abnormal muscle mass. Studies have shown that cystatin C is a more sensitive marker of early renal dysfunction than creatinine, often rising before creatinine levels exceed normal ranges. Cystatin C has been incorporated into newer eGFR equations, including the KDIGO CKD-EPI combined creatinine-cystatin model, enhancing the accuracy of GFR estimates, particularly in early-stage renal disease. Despite its utility, cystatin C is not without limitations. Its concentration may be influenced by thyroid disorders, certain malignancies, and smoking. Evidence indicates that hyperthyroidism can increase cystatin C levels independently of renal function due to increased cellular production [24].

Albuminuria and Proteinuria

Albuminuria refers to the abnormal presence of albumin in the urine, a key indicator of glomerular dysfunction. The term "microalbuminuria" is no longer used, as it suggests the presence of a distinct biochemical entity, which is inaccurate. Instead, urine albumin levels are now referred to as normal, moderately increased, or severely increased. Albuminuria serves as an early marker for diabetic nephropathy and is independently associated with cardiovascular disease risk, likely to reflect widespread endothelial dysfunction. It is also used as a diagnostic criterion for chronic kidney disease (CKD) and progression monitoring. Urine albumin can be measured using 24-hour collections or through spot testing, most commonly by calculating the albumin-to-creatinine ratio (ACR) from a

random or early morning urine sample. Persistent albuminuria, confirmed on at least two occasions and in the absence of urinary tract infection, reflects ongoing glomerular damage. If albuminuria continues for three months or more, it fulfills the criteria for CKD diagnosis. Frank proteinuria is defined as urinary protein excretion exceeding 300 mg per day. In contrast, normal protein excretion is up to 150 mg daily and consists of approximately 30–40% albumin, 10–20% globulins, and about 50% uromodulin (also known as Tamm-Horsfall protein) [25]. Increases in urinary protein can arise from several mechanisms. Glomerular proteinuria is due to altered filtration barrier permeability, seen in conditions like glomerulonephritis and nephrotic syndrome. Tubular proteinuria results from defective reabsorption in the proximal tubules, such as in interstitial nephritis. Overflow proteinuria is a consequence of elevated plasma concentrations of low-molecular-weight proteins, such as Bence-Jones proteins in multiple myeloma or myoglobin in rhabdomyolysis. Proteinuria may also originate from urinary tract inflammation or tumors [25].

Quantifying proteinuria can be done through a full 24-hour urine collection or by estimating the protein-to-creatinine ratio in a spot urine sample. Early morning samples are preferred because they most closely correlate with total daily excretion, offering greater diagnostic reliability. The KDIGO guidelines categorize albuminuria into three stages to assist in clinical staging and treatment planning. Stage A1 denotes less than 30 mg of albumin per gram of creatinine, A2 represents levels between 30 and 300 mg/g, and A3 indicates values exceeding 300 mg/g. These thresholds help determine disease severity and inform prognosis. In nephrotic syndrome, urine protein excretion surpasses 3.5 g per day and is typically accompanied by hypoalbuminemia, peripheral edema, and elevated cholesterol levels. These clinical features reflect massive protein losses, reduced oncotic pressure, and compensatory hepatic lipid production. Accurate identification and monitoring of albuminuria and proteinuria are central to the early diagnosis and ongoing management of chronic kidney disease, especially in patients with diabetes, hypertension, or cardiovascular risk. The integration of albuminuria measurements alongside eGFR improves risk stratification and treatment efficacy across a range of renal pathologies [25].

Tubular Function Tests

The renal tubules are responsible for critical physiological processes including electrolyte reabsorption, water conservation, and acid-base regulation. These processes are essential for maintaining homeostasis and the effective functioning of organ systems. Electrolytes such as sodium, potassium, chloride, phosphate, and magnesium, as well as glucose, are reabsorbed or secreted within the tubules and can be quantitatively assessed through urine analysis. Urine osmolality is a key measure of the kidneys' ability to concentrate or dilute urine and reflects tubular function. A urinary osmolality exceeding 750 mOsm/kg H_2O indicates normal concentrating ability. Tubular function can be further evaluated using specific diagnostic tests. For instance, the water deprivation test is employed to differentiate central from nephrogenic diabetes insipidus. If the kidneys fail to respond appropriately by concentrating the urine despite dehydration, nephrogenic diabetes insipidus is likely. In suspected cases of distal renal tubular acidosis, the ammonium chloride test can be used. A failure to acidify the urine to a pH below 5.3 after administration of ammonium chloride confirms the diagnosis. Fanconi syndrome, characterized by generalized proximal tubular dysfunction, presents glycosuria, aminoaciduria, phosphaturia, and bicarbonate waste, indicative of proximal renal tubular acidosis [25].

Urine Analysis

Urine analysis is a routine diagnostic test that involves physical, chemical, and microscopic examination of urine to detect a wide array of renal and systemic conditions. Physically, urine is evaluated for color and clarity. Normal urine appears straw-colored and clear. Dark urine may suggest dehydration, while red discoloration can indicate hematuria, porphyria, or ingestion of certain foods like beets. Cloudiness is often associated with urinary tract infections and the presence of pus cells or bacteria. Specific gravity assesses the kidney's ability to concentrate urine and can be measured using a refractometer or chemically via dipstick. Normal values range from 1.003 to 1.030. A higher specific gravity suggests concentrated urine, as seen in dehydration, whereas lower values reflect dilute urine, which may occur in diabetes insipidus or overhydration. Urine dipsticks offer rapid, point-of-care chemical analysis of several urinary components. These include protein, glucose, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase. Each analyte produces a specific color change on the strip when reacted with its reagent, which is compared against a standardized color chart. In healthy individuals, urine typically tests negative for protein, glucose, bilirubin, blood, and ketones. However, certain physiological and pathological conditions can alter these findings. Glucose in urine suggests diabetes mellitus or, less commonly, renal glycosuria or pregnancy. Ketones appear in fasting states, severe vomiting, and diabetic ketoacidosis. Notably, the dipstick does not detect beta-hydroxybutyrate, the main ketone in diabetic ketoacidosis [26].

Blood detected on dipstick may originate from hematuria, hemoglobinuria, or myoglobinuria. The test detects the globin component, making it unable to differentiate between hemoglobin and myoglobin. False negatives may occur in the presence of ascorbic acid. A positive dipstick for blood with absent red blood cells (RBCs) on microscopy indicates rhabdomyolysis and myoglobinuria. Normal values on microscopic urinalysis are 0–3 RBCs and 0–5 white blood cells (WBCs) per high-power field. Bilirubin is only detected in conjugated hyperbilirubinemia, while urobilinogen is typically present in small amounts and increases in prehepatic jaundice or hemolysis. Nitrite and leukocyte esterase suggest urinary

tract infection. Nitrite is formed when bacteria reduce nitrate to nitrite, a reaction common with Enterobacteriaceae. Microscopic urinalysis involves examining a centrifuged urine sample under the microscope to detect cells, casts, crystals, and organisms. RBC casts are associated with glomerulonephritis, and WBC casts with pyelonephritis. Hyaline casts may appear in concentrated urine or glomerular diseases. Fatty casts are often present in nephrotic syndrome. Crystals provide clues to specific metabolic or toxic conditions. For example, triple phosphate crystals (coffin-lid shaped) are found in alkaline urine and urinary tract infections, uric acid crystals (needle-shaped) indicate gout, oxalate crystals (envelope-shaped) are seen in ethylene glycol poisoning, and cystine crystals (hexagonal) are observed in cystinuria. A fresh midstream urine sample is preferred for accuracy and reduced contamination [26].

Acute Versus Chronic Renal Impairment

Renal impairment is classified as acute or chronic based on duration and underlying etiology. Acute kidney injury (AKI) refers to a rapid decline in kidney function over hours or days, whereas chronic kidney disease (CKD) reflects long-term, progressive loss of renal function, commonly caused by hypertension and diabetes mellitus. Causes of AKI are classified into pre-renal, intrinsic, and post-renal. Pre-renal causes include hypovolemia, shock, or blood loss leading to reduced renal perfusion. Intrinsic causes involve direct injury to renal tissues from nephrotoxins, ischemia, infection, or autoimmune diseases. Post-renal causes involve obstruction of urine outflow due to malignancy, stones, or strictures. Pre-renal AKI can lead to acute tubular necrosis if not corrected. Urine output is a key marker for AKI, with oliguria defined as output less than 400 mL/day or under 0.5 mL/kg/h for six hours. The RIFLE and AKIN criteria use changes in serum creatinine, urine output, and GFR to classify the severity of AKI. AKIN criteria do not require a baseline creatinine or rely on GFR estimation. Several tests help determine the origin of renal injury. Increased urine specific gravity (>1.020) often indicates pre-renal causes. Microscopic evaluation shows WBCs, RBCs, epithelial cells, or casts helps differentiate between pathologies [26]. Measurement of fractional excretion of sodium (FeNa) is another important tool. FeNa is calculated with the formula:

FeNa (%) = 100 × (urinary sodium × serum creatinine) / (serum sodium × urinary creatinine)

Values below 1% are typical of pre-renal causes, while values above 2% suggest intrinsic injury. A spot urine sodium level below 20 mmol/L also supports a pre-renal diagnosis. In patients on diuretics, FeNa becomes unreliable, and the fractional excretion of urea (<35%) becomes a more appropriate alternative. Urine osmolality greater than 500 mOsm/kg points to pre-renal injury, while values near 300 mOsm/kg suggest tubular dysfunction.

Novel Biomarkers

Emerging biomarkers provide better sensitivity and specificity for diagnosing AKI, differentiating it from CKD and distinguishing pre-renal from intrinsic causes. These biomarkers fall into two main categories. The first group consists of filtration markers present in systemic circulation, including cystatin C, beta-2-microglobulin, and retinol-binding protein. Recently identified markers include pseudouridine, acetylthreonine, myoinositol, phenylacetylglutamine, and tryptophan [14]. The second group includes proteins expressed in response to cellular or tubular injury. These include neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), L-type fatty acid-binding protein (L-FABP), fibroblast growth factor 23 (FGF23), and beta-trace protein. These markers hold potential in refining the diagnosis, staging, and monitoring of AKI, but their routine clinical use requires further validation through research. Continued investigation into these markers will likely enhance the precision of renal diagnostics, providing earlier detection, better differentiation between disease types, and more effective intervention strategies [14].

Indications:

Renal function assessment serves multiple clinical purposes across both acute and chronic care settings. The primary reason for conducting these tests is to detect the presence of renal disease and evaluate the extent of impairment, allowing for timely and appropriate patient management. Early identification of renal dysfunction helps guide decisions on interventions that may prevent further decline in kidney function. In patients already diagnosed with renal disease, functional assessment supports the staging and classification of the disorder. Determining whether the damage is glomerular, tubular, or both assists in refining the diagnosis and selecting targeted treatment strategies. Repeated testing is used to monitor disease progression and assess the efficacy of interventions, including medications or lifestyle changes. Monitoring also ensures that management adjustments are made promptly to avoid complications or progression to end-stage renal disease. Another important indication is the initiation or use of medications known to affect renal function, such as nonsteroidal anti-inflammatory drugs, aminoglycosides, or contrast agents. In these cases, renal function testing is necessary both before and during treatment to prevent nephrotoxicity and adjust dosages accordingly. Testing is also critical in the pre-transplant evaluation process for kidney donors. It ensures that the donor's renal function is sufficient for donation and that the remaining kidney can sustain normal function post-donation. Continued testing postoperatively helps monitor any decline in kidney performance [26][27][28]. In selected cases, renal function tests help pinpoint which segment of the nephron is compromised—such as distinguishing between glomerular or tubular injury—providing important diagnostic and therapeutic direction [29][30].

Table-1: Renal Function Tests.

Test/Parameter	**Purpose**	**Normal Range / Reference**	**Clinical Use**
Glomerular Filtration Rate (GFR)	Estimates glomerular function	90–125 mL/min/1.73 m² (adults)	Detects CKD stage, assesses kidney function, guides therapy
Serum Creatinine	Endogenous marker for GFR	Men: ~0.7–1.3 mg/dL, Women: ~0.6–1.1 mg/dL	Used in eGFR formulas (CKD-EPI, MDRD), detects renal impairment
Creatinine Clearance	Measures filtered creatinine	~90–140 mL/min (varies by age, gender, body surface)	GFR estimation, drug dosing
Blood Urea Nitrogen (BUN)	Assesses nitrogen waste elimination	7–20 mg/dL	Used with creatinine to differentiate pre-renal vs renal causes
BUN/Creatinine Ratio	Differentiates causes of uremia	Normal: ~10:1; Pre-renal: ~20:1; GI bleed: >30:1	Suggests etiology of elevated BUN
Cystatin C	Alternative GFR marker	~0.6–1.0 mg/L (varies with lab)	Early detection of kidney impairment, especially when creatinine is unreliable
Albuminuria	Marker of glomerular damage	A1: <30 mg/g; A2: 30–300 mg/g; A3: >300 mg/g creatinine	Detects diabetic nephropathy, cardiovascular risk, CKD staging
Proteinuria	Total urinary protein detection	Normal: <150 mg/day; Nephrotic: >3.5 g/day	damage indicator
Urine Specific Gravity	Measures urine concentration	1.003–1.030	Assesses hydration and tubular function
Urine Osmolality	Measures tubular concentrating ability	>750 mOsm/kg H_2O (normal concentration)	Used in diabetes insipidus and acute kidney injury diagnosis
Urine Dipstick	Point-of-care screen for multiple analytes	Qualitative	Detects protein, blood, glucose, ketones, nitrite, leukocyte esterase
Microscopic Urinalysis	Identifies cells, casts, crystals	RBC: 0–3/HPF, WBC: 0–5/HPF	Diagnoses glomerulonephritis, infection, crystals in metabolic disorders
Fractional Excretion of Sodium (FeNa)	Differentiates pre-renal vs. intrinsic AKI	<1% = pre-renal, >2% = intrinsic	Assesses acute kidney injury cause
Fractional Excretion of Urea (FeUrea)	Alternative to FeNa if diuretics used	<35% = pre-renal	Useful in differentiating AKI causes
Novel Biomarkers	Early AKI and CKD detection	Variable (depends on assay and marker)	NGAL, KIM-1, L-FABP, FGF23 offer earlier and more specific detection

Potential Diagnosis:

Renal function tests play a central role in diagnosing various renal and systemic conditions. By directly measuring or estimating the glomerular filtration rate (GFR), clinicians can assess overall renal performance and determine the degree of functional impairment. Estimating GFR helps in identifying both early and advanced stages of renal disease and is essential in distinguishing between acute and chronic renal disorders. Chronic kidney disease (CKD), for example, may not always present obvious symptoms, and GFR calculation aids in its

detection and staging. Urine albumin levels are particularly useful in identifying early kidney damage in high-risk individuals, such as those with diabetes or hypertension. Albuminuria, even at low levels, signals glomerular injury and, if persistent, confirms the presence of chronic kidney disease. Tracking changes in albumin excretion over time also helps assess treatment response and disease progression. More specialized tubular function tests expand diagnostic capabilities. For example, in Fanconi syndrome, detailed urine studies may reveal losses of amino acids, glucose, phosphate, and bicarbonate, suggesting generalized proximal tubular dysfunction. Similarly, abnormalities in urinary pH or electrolytes can help identify distal renal tubular acidosis or conditions affecting water and salt handling [29][30]. Overall, renal function tests support clinical evaluation by confirming suspected diagnoses, identifying asymptomatic kidney disease, and guiding treatment. Their application ranges from screening and early detection in high-risk populations to complex diagnostic workups in suspected hereditary or acquired tubular disorders. These tests also help in evaluating structural-functional relationships within the nephron, providing localized insight into glomerular or tubular pathology [29][30].

Normal and Critical Findings:

The normal range for GFR in adults is approximately 90 to 125 mL/min in individuals over two years old. A GFR below 15 mL/min is indicative of end-stage renal disease and generally necessitates dialysis or renal replacement therapy. However, a normal GFR does not automatically exclude kidney disease. Patients may exhibit normal filtration rates while still having structural or functional abnormalities, such as albuminuria or imaging abnormalities. Reference values for serum creatinine and urea vary based on age, sex, muscle mass, and other physiological variables. Creatinine levels are typically higher in males due to increased muscle mass. These values should be interpreted in conjunction with clinical context and not in isolation. A modestly elevated creatinine in elderly, low-muscle-mass individual may still reflect significant renal dysfunction. Urea, or blood urea nitrogen (BUN), also has a broad reference interval. Its level can fluctuate based on protein intake, hydration status, and metabolic conditions. As such, a single elevated BUN without supporting findings may not indicate renal disease. Electrolyte concentrations in urine—such as sodium, potassium, and phosphate—are influenced by both physiological and pathological conditions. Factors like fluid status, dietary intake, and duration of urine collection significantly affect their interpretation. Reference intervals for urine electrolytes are often wide, and deviations must be evaluated with respect to clinical history, medications, and associated symptoms. Monitoring GFR trends, serum creatinine, and albuminuria together provides a more comprehensive assessment of renal function than any single test [29][30] [31].

Factors Interfering:

Numerous factors can interfere with the interpretation of renal function tests, particularly those involving creatinine, BUN, and urine proteins. For serum creatinine, high-protein diets or increased muscle mass can result in falsely elevated levels, potentially leading to misinterpretation of renal status. Conversely, individuals with low muscle mass, including the elderly or those with muscle-wasting conditions, may have deceptively low creatinine levels despite underlying kidney dysfunction. Creatinine measurement is commonly done using either the Jaffe reaction or enzymatic methods. The Jaffe method, although cost-effective, is vulnerable to interferences. Substances such as bilirubin may suppress color development, leading to falsely low values, while ketones and proteins may elevate the results. These factors can complicate diagnosis if not accounted for. BUN levels also show variability due to factors unrelated to renal health. A high-protein diet or the use of corticosteroids can raise BUN without underlying kidney pathology. Similarly, gastrointestinal bleeding and tissue catabolism can elevate BUN independently of renal clearance. Urine albumin or protein levels may be transiently increased by factors like posture, exercise, and fever. In urinary tract infections, inflammation may raise urinary protein levels even in the absence of intrinsic renal disease. Therefore, positive findings should be confirmed with repeat testing in a stable clinical state, and infections must be ruled out. Accurate interpretation of renal function tests requires a comprehensive understanding of physiological and methodological influences to avoid diagnostic errors and unnecessary interventions [29][30].

Complications

Renal function tests are generally safe, but minor complications can arise, especially from sample collection procedures. Blood sampling for serum creatinine, BUN, and other parameters may cause localized pain, bruising, or hematoma at the puncture site. These are typically mild and resolved without intervention. Some advanced GFR assessment techniques involve the use of radioactive isotopes or contrast agents. Although these methods provide precise measurements, they pose specific risks. For example, isotopic methods result in low-level radiation exposure. While usually considered safe, repeated testing over short intervals is discouraged to minimize cumulative exposure. Use of contrast agents, particularly iodinated compounds used during imaging or GFR measurement, may provoke allergic reactions. These reactions range from mild rashes to severe anaphylaxis, although such outcomes are rare. Additionally, contrast-induced nephropathy remains a concern, especially in patients with pre-existing renal impairment or dehydration. Collection of 24-hour urine samples may require preservatives such as thymol. These chemicals are generally safe if used correctly but can irritate the skin or mucous membranes upon contact. If accidentally ingested, especially by children, these preservatives can be toxic. Complications are minimized when proper technique, patient education, and safety precautions are observed. Risk assessment prior to using isotopes or contrast is critical,

particularly in vulnerable populations such as pregnant women, elderly patients, and those with multiple comorbidities. The benefits of testing must be weighed against potential risks in each case to ensure responsible and informed clinical practice [29][30].

Patient Safety and Education

Ensuring patient safety during renal function testing involves clear communication, proper technique, and risk mitigation. For tests involving radioactive isotopes to measure GFR, patients should be informed about the exposure to low-dose ionizing radiation. Any woman of reproductive age should undergo pregnancy screening before the procedure to avoid fetal exposure. Patients should also be informed about common side effects of venipuncture. These include localized pain, bruising, and in rare cases, infection. Educating patients about post-procedure care—such as applying pressure to the site and monitoring for swelling—can reduce complications. For 24-hour urine collection, patients must receive detailed instructions to ensure proper collection technique. The use of collection containers with preservatives like thymol carries safety considerations. Patients should avoid skin or mucous membrane contact and keep containers out of reach of children to prevent accidental ingestion or exposure [32]. Maintaining adequate hydration is advised prior to and during collection to ensure accurate results. Dehydration can influence several renal parameters, including creatinine, BUN, and urine osmolality, potentially leading to misdiagnosis. Patients should also be aware that some medications and supplements can interfere with test results. For example, vitamin C supplements can cause false-negative dipstick results for blood, nitrites, and glucose. A full medication history should be reviewed before testing. Overall, patient education enhances test accuracy and minimizes adverse outcomes. Providing written instructions, verifying understanding, and offering follow-up guidance ensures safer and more effective use of renal function diagnostics [32].

Clinical Significance:

Renal function tests provide essential information for diagnosing, staging, and monitoring kidney disease. Serum creatinine is a widely used marker for estimating GFR and detecting renal dysfunction. However, it is a late marker of disease; approximately 50% of renal function must be lost before a measurable rise in serum creatinine occurs. As a result, creatinine alone may fail to detect early renal impairment, particularly in acute kidney injury or among individuals with low muscle mass. BUN is another key indicator that rises in both acute and chronic renal failure. However, it is less specific than creatinine and can be influenced by non-renal factors, including diet, hydration, and catabolism. Despite these limitations, both markers are central to equations that estimate GFR, such as the MDRD or CKD-EPI formulas, which are routinely used in clinical practice to guide diagnosis and treatment planning. These values help determine the stage of chronic kidney disease and whether a patient requires further evaluation, referral to a nephrologist, or initiation of treatment. They also assist in monitoring therapeutic response and making informed decisions about medication dosing, particularly for renally-excreted drugs. Additionally, trends in creatinine and BUN levels are often more clinically relevant than single values. Serial measurements allow clinicians to assess disease trajectory, treatment efficacy, and potential complications. Given the known limitations of traditional markers, ongoing research into earlier and more reliable biomarkers continues to shape the future of nephrology diagnostics [32].

Conclusion:

Renal function assessment is fundamental in diagnosing and managing kidney disease, with clinical pathologists and laboratory technicians playing a pivotal role in ensuring accurate and reliable test results. Traditional markers such as serum creatinine and BUN remain widely used for estimating GFR and detecting renal impairment, but they have limitations, including delayed sensitivity in early disease and susceptibility to non-renal influences. The development of more precise equations, such as CKD-EPI, and the incorporation of cystatin C have improved GFR estimation, particularly in diverse populations. Albuminuria serves as a crucial early indicator of glomerular damage, especially in diabetic nephropathy, while tubular function tests help identify specific renal pathologies. Emerging biomarkers, including NGAL and KIM-1, offer potential for earlier and more accurate detection of acute kidney injury, though further validation is needed before widespread clinical adoption. Patient safety and education are essential, particularly in procedures involving radioactive isotopes or contrast agents. Proper specimen collection and awareness of interfering factors—such as diet, hydration, and medications—are critical to avoid misinterpretation of results. In summary, while conventional renal function tests remain indispensable, advancements in biomarkers and diagnostic techniques continue to refine kidney disease assessment. A multidisciplinary approach, integrating laboratory expertise with clinical evaluation, ensures optimal patient management. Future research should focus on validating novel biomarkers and refining GFR estimation methods to enhance early detection and personalized treatment strategies for renal disorders.

References:

1. Okoro RN, Farate VT. The use of nephrotoxic drugs in patients with chronic kidney disease. Int J Clin Pharm. 2019 Jun;41(3):767-775.
2. Nwose EU, Obianke J, Richards RS, Bwitit PT, Igumbor EO. Prevalence and correlations of hepatorenal functions in diabetes and cardiovascular disease among stratified adults. Acta Biomed. 2019 Jan 22;90(1):97-103.
3. Damiati S. A Pilot Study to Assess Kidney Functions and Toxic Dimethyl-arginines as Risk Biomarkers in Women with Low Vitamin D Levels. J Med Biochem. 2019 Apr;38(2):145-152.
4. Rodríguez-Cubillo B, Carnero-Alcázar M, Cobiella-Carnicer J, Rodríguez-Moreno A, Alswies A, Velo-

Plaza M, Pérez-Camargo D, Sánchez Fructuoso A, Maroto-Castellanos L. Impact of postoperative acute kidney failure in long-term survival after heart valve surgery. Interact Cardiovasc Thorac Surg. 2019 Jul 01;29(1):35-42.

5. Gai Z, Wang T, Visentin M, Kullak-Ublick GA, Fu X, Wang Z. Lipid Accumulation and Chronic Kidney Disease. Nutrients. 2019 Mar 28;11(4)
6. Kamianowska M, Szczepański M, Wasilewska A. Tubular and Glomerular Biomarkers of Acute Kidney Injury in Newborns. Curr Drug Metab. 2019;20(5):332-349.
7. Wiles K, Bramham K, Seed PT, Nelson-Piercy C, Lightstone L, Chappell LC. Serum Creatinine in Pregnancy: A Systematic Review. Kidney Int Rep. 2019 Mar;4(3):408-419.
8. Denic A, Glassock RJ, Rule AD. Structural and Functional Changes With the Aging Kidney. Adv Chronic Kidney Dis. 2016 Jan;23(1):19-28.
9. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den Heijer M. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney Int. 2007 Sep;72(5):632-7.
10. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS., CKD-EPI Investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012 Jul 05;367(1):20-9.
11. Teo BW, Koh YY, Toh QC, Li J, Sinha AK, Shuter B, Sethi S, Lee EJ. Performance of the CKD-EPI creatinine-cystatin C glomerular filtration rate estimation equations in a multiethnic Asian population. Singapore Med J. 2014 Dec;55(12):656-9.
12. Hundemer GL, White CA, Norman PA, Knoll GA, Tangri N, Sood MM, Hiremath S, Burns KD, McCudden C, Akbari A. Performance of the 2021 Race-Free CKD-EPI Creatinine- and Cystatin C-Based Estimated GFR Equations Among Kidney Transplant Recipients. Am J Kidney Dis. 2022 Oct;80(4):462-472.e1.
13. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Gutiérrez OM, Kalil R, Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby R, Rossing P, Rule AD, Selvin E, Seegmiller JC, Shlipak MG, Torres VE, Yang W, Ballew SH, Couture SJ, Powe NR, Levey AS., Chronic Kidney Disease Epidemiology Collaboration. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021 Nov 04;385(19):1737-1749.
14. Levey AS, Titan SM, Powe NR, Coresh J, Inker LA. Kidney Disease, Race, and GFR Estimation. Clin J Am Soc Nephrol. 2020 Aug 07;15(8):1203-1212.
15. Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA, Mendu ML, Miller WG, Moxey-Mims MM, Roberts GV, St Peter WL, Warfield C, Powe NR. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am J Kidney Dis. 2022 Feb;79(2):268-288.e1.
16. Quaggin SE, Palevsky PM. Removing Race from Kidney Disease Diagnosis. Am J Kidney Dis. 2022 Feb;79(2):153-155.
17. Avilez ND, Nolazco JI, Chang SL, Reis LO. Urological impact of race-free estimated glomerular filtration rate equations. Int Braz J Urol. 2023 Nov-Dec;49(6):665-667.
18. Ottosson Frost C, Gille-Johnson P, Blomstrand E, St-Aubin V, Leion F, Grubb A. Cystatin C-based equations for estimating glomerular filtration rate do not require race or sex coefficients. Scand J Clin Lab Invest. 2022 Apr;82(2):162-166.
19. Li T, Grams ME, Inker LA, Chen J, Rhee EP, Warady BA, Levey AS, Denburg MR, Furth SL, Ramachandran VS, Kimmel PL, Coresh J. Consistency of metabolite associations with measured glomerular filtration rate in children and adults. Clin Kidney J. 2024 Jun;17(6):sfae108.
20. Jalalonmuhali M, Lim SK, Md Shah MN, Ng KP. MDRD vs. CKD-EPI in comparison to ^{51}Chromium EDTA: a cross sectional study of Malaysian CKD cohort. BMC Nephrol. 2017 Dec 13;18(1):363.
21. Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976 Aug;58(2):259-63.
22. Björk J, Nyman U, Larsson A, Delanaye P, Pottel H. Estimation of the glomerular filtration rate in children and young adults by means of the CKD-EPI equation with age-adjusted creatinine values. Kidney Int. 2021 Apr;99(4):940-947.
23. De Souza VC, Rabilloud M, Cochat P, Selistre L, Hadj-Aissa A, Kassai B, Ranchin B, Berg U, Herthelius M, Dubourg L. Schwartz formula: is one k-coefficient adequate for all children? PLoS One. 2012;7(12):e53439.
24. Tapper M, McGrowder DA, Dilworth L, Soyibo A. Cystatin C, Vitamin D and Thyroid Function Test Profile in Chronic Kidney Disease Patients. Diseases. 2021 Jan 03;9(1)
25. Haider MZ, Aslam A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Sep 4, 2023. Proteinuria.
26. Lee W, Kim Y, Chang S, Lee AJ, Jeon CH. The influence of vitamin C on the urine dipstick tests in the clinical specimens: a multicenter study. J Clin Lab Anal. 2017 Sep;31(5)
27. Klein SJ, Lehner GF, Forni LG, Joannidis M. Oliguria in critically ill patients: a narrative review. J Nephrol. 2018 Dec;31(6):855-862.
28. Haider MZ, Aslam A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 31, 2023. Oliguria.

29. Hounkpatin HO, Fraser SDS, Glidewell L, Blakeman T, Lewington A, Roderick PJ. Predicting Risk of Recurrent Acute Kidney Injury: A Systematic Review. Nephron. 2019;142(2):83-90.
30. Boga MS, Sönmez MG. Long-term renal function following zero ischemia partial nephrectomy. Res Rep Urol. 2019;11:43-52.
31. Jančič SG, Močnik M, Marčun Varda N. Glomerular Filtration Rate Assessment in Children. Children (Basel). 2022 Dec 19;9(12)
32. Gounden V, Bhatt H, Jialal I. Renal function tests. InStatPearls [Internet] 2024 Jul 27. StatPearls Publishing.